从概念到临床：视黄酸受体α拮抗剂YCT-529，口服非激素男性避孕药。

IF 3.4 2区医学 Q1 ANDROLOGY

Andrology Pub Date : 2025-08-12 DOI:10.1111/andr.70106

Noha Taher, Ehfazul Haque, Gunda I Georg

引用次数: 0

摘要

YCT-529可逆地将小鼠和非人类灵长类动物的精子数量减少到不育水平。老鼠交配研究表明，99%的有效性防止怀孕。YCT-529已经完成了一项同类第一、双盲、安慰剂对照的男性I期临床安全性研究，目前正在进行Ib/IIa期临床研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

From concept to the clinic: Retinoic acid receptor α antagonist YCT-529, an oral non-hormonal male contraceptive.

YCT-529 reversibly reduces sperm counts to infertility levels in mice and non-human primates. Mice mating studies demonstrated 99% effectiveness in preventing pregnancies. YCT-529 has completed a first-in-class, double-blind, placebo-controlled Phase I clinical safety study in men and is currently being investigated in a Phase Ib/IIa clinical study.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Andrology ANDROLOGY-

CiteScore

9.10

自引率

6.70%

发文量

200

期刊介绍： Andrology is the study of the male reproductive system and other male gender related health issues. Andrology deals with basic and clinical aspects of the male reproductive system (gonads, endocrine and accessory organs) in all species, including the diagnosis and treatment of medical problems associated with sexual development, infertility, sexual dysfunction, sex hormone action and other urological problems. In medicine, Andrology as a specialty is a recent development, as it had previously been considered a subspecialty of urology or endocrinology